ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has been issued a patent from the U.S. Patent and Trademark Office claiming methods for treating, preventing, inhibiting or reducing tissue deterioration due to congestive heart failure disease using Thymosin beta 4 (Tß4), its isoforms and fragments, and important analogs. Patent No. 8,093,214 is projected to expire in July 2027.
